Compare Cytokinetics Inc (CYTK) vs MasTec Inc (MTZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs MasTec Inc — how do they compare? Cytokinetics Inc trades at $76.56 (market cap $10.63B), while MasTec Inc trades at $281.88 (market cap $21.90B). The key difference: MasTec Inc is far larger — about 2.1× Cytokinetics Inc's market cap, and Cytokinetics Inc is trading nearer its 52-week high, MasTec Inc nearer its low. Which is the better fit depends on your goals.
| CYTK | MTZ | |
|---|---|---|
Market Cap | $10.63B | $21.90B |
Sector | Technology | Technology |
52-Week High | $87.26 | $437.51 |
52-Week Low | $34.31 | $172.51 |
Enterprise Value | $10.74B | $24.81B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $77.07, down 0.54% on the day, with a bearish technical signal from moving averages. The company reported a Q2 2026 loss of $1.50 per share, beating estimates, but revenue of $68 million in 2026 reflects a net loss margin of -1,321.12%. Recent UK approval for MYQORZO and positive NICE guidance provide commercial momentum, yet high SG&A costs and negative cash flow from operations highlight ongoing financial strain.
The outlook hinges on MYQORZO's commercial execution and label expansion, with a consensus price target of $111.14 implying 44% upside. Risks include sustained cash burn, competitive pressure, and reliance on aficamten's clinical success. Analyst sentiment is overwhelmingly bullish, but profitability remains distant.
MasTec (MTZ) trades at $283.76, up 5.77% over 24 hours, with a bearish technical signal but strong fundamentals. The company reported record Q2 2026 revenue of $4.374 billion, up 23% year-over-year, and raised its full-year outlook. Analyst consensus is overwhelmingly bullish with a $439.56 price target, though technical indicators show resistance near $283.
The outlook remains positive due to robust infrastructure demand, a record $21.4 billion backlog, and strategic acquisitions like The Superior Group. Risks include execution challenges in communications segments and high valuation multiples. Earnings growth and backlog execution are key catalysts for further upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About MasTec Inc
MasTec, Inc. is a leading infrastructure construction company operating mainly in North America. The company's services cover a diverse range of end-markets, including communications (building fiber and wireless infrastructure), oil & gas, electric power (transmission, distribution, and clean energy), and industrial projects. MTZ provides critical engineering, procurement, and construction (EPC) services that support the expansion and maintenance of essential infrastructure across the continent.
Read more on MTZ →
